Article citationsMore>>

Abboud, N., Ghazouani, L., Saidi, S., Ben-Hadj-Khalifa, S., Addad, F., Almawi, W.Y. and Mahjoub, T. (2010) Association of PAI-1 4G/5G and -844G/A gene polymorphisms and changes in PAI-1/tissue plasminogen activator levels in myocardial infarction: A case-control study. Genetic Testing and Molecular Biomarkers, 14(1), 23- 27.

has been cited by the following article:

• TITLE: Association of the plasminogen activator inhibitor-1(PAI-1) gene 4G/5G promoter polymorphism in Buerger's disease (Tromboangiitis obliterans)

  AUTHORS: Sinasi Manduz, Nurkay Katrancioglu, Oguz Karahan, Oztürk Ozdemir

  KEYWORDS: Thromboangiitis Obliterans; Genetic Polymorphisms; PAI-1

  JOURNAL NAME: Health, Vol.2 No.5, May 27, 2010

  ABSTRACT: Thromboangiitis obliterans (TAO) is an unusual tobacco-associated vasculopathy that is a non- atherosclerotic inflammatory disorder of unkn- own etiology that affects small and medium- sized vessels of the extremities. The single guanosine nucleotide deletion/insertion polym- orphism (4G/5G) at -675 bp in promoter region of the PAI-1 gene is the major genetic determi- nant of PAI-1 expression. Plasma PAI-1 level is higher in people with the homozygous 4G genotype than in those with the 5G/5G genotype and renders higher transcription activity. The aim of this study was to determine the status and the role of PAI-1 gene 4G/5G promoter polymorphism in patients with Buerger's disease (Thromboangiitis obliterans—TAO). The current case-control study included 30 consecutive pat- ients with Buerger's disease (mean age 42.9 ± 14.3 years, 28 men and 2 women), and 30 healthy volunteers (mean age 40.9 ± 4.79 years, 27 men and 3 women) between January 2006 and September 2009. Patients and control cases were genotyped for the 4G/5G polymorphism using the multiplex PCR based stripassay reverse hybridisation technique. It was found that heterozygote PAI-1 gene polymorphisms (p